direct antithrombins

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultMajor bleedingAll cause death

atrial fibrillation

dabigatran
RE-LY (110mg), 2009      NCTdabigatran 110mgwarfarin standard doseRisk of bias suggesting-20%-9%
PETRO (150mg), 2007     dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009      NCTdabigatran 150mgwarfarin standard doseRisk of bias suggesting -7%-12%
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002     ximelagatranwarfarin standard doseRisk of bias -
SPORTIF III, 2003     ximelagatranwarfarin standard doseRisk of bias suggesting-29%-1%
SPORTIF V, 2005       ximelagatranwarfarin standard doseLow risk of bias suggesting -25%-6%

thrombosis prevention

dabigatran
RE-NOVATE (150mg), 2007      NCTdabigatran 150mgenoxaparinhip surgeryLow risk of bias negative -17%
RE-NOVATE (220mg), 2007      NCTdabigatran 220mgenoxaparinhip surgeryLow risk of bias negative29%+Infini%
RE-NOVATE 2    NCTdabigatran 220mgenoxaparinhip surgeryLow risk of bias negative
RE-MODEL (150mg), 2007     dabigatran 150mgenoxaparin (europe regimen)knee surgeryLow risk of bias negative-1%-2%
RE-MODEL (220mg), 2007   dabigatran 220mgenoxaparin (europe regimen)knee surgeryLow risk of bias negative14%1%
RE-MOBILIZE (150mg), 2008     dabigatran 150mgenoxaparin (US regimen)knee surgeryLow risk of bias negative -58%+Infini%
RE-MOBILIZE (220mg), 2008     dabigatran 220mgenoxaparin (US regimen)knee surgeryLow risk of bias negative -58%
ximelagatran
METHRO I, 2002   ximelagatranDalteparinnegative
METHRO II, 2002     ximelagatranDalteparinLow risk of bias suggesting101%
Phase II (Heit), 2001     ximelagatranEnoxaparinLow risk of bias negative-100%
Platinum (Colwell), 2003   ximelagatranEnoxaparinLow risk of bias negative -12%
METHRO III, 2002         ximelagatranEnoxaparinLow risk of bias negative-14%
EXPRESS, 2003     ximelagatranEnoxaparinLow risk of bias suggesting 189%